Jyske Bank
22.3.2021 07:58:00 CET | Globenewswire | Press release
The share repurchase programme runs as from 28 January 2021 and up to and including 30 September 2021. In this period, Jyske Bank will acquire shares with a value of up to DKK 750 million, cf. Corporate Announcement No. 2/2021 of 28 January 2021. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called "Market Abuse Regulation".
The following transactions have been made under the program:
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Accumulated, latest announcement | 593,925 | 255.11 | 151,514,749 |
| 15 March 2021 | 16,000 | 277.51 | 4,440,171 |
| 16 March 2021 | 15,654 | 280.73 | 4,394,568 |
| 17 March 2021 | 15,700 | 280.49 | 4,403,618 |
| 18 March 2021 | 15,750 | 286.18 | 4,507,285 |
| 19 March 2021 | 15,222 | 284.10 | 4,324,512 |
| Accumulated under the programme | 672,251 | 258.21 | 173,584,903 |
With the transactions stated above, Jyske Bank now owns a total of 672,251 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 0.93% of the share capital.
In accordance with the EU Commission Regulation No. 596/2014, transactions related to the share buy-back programme are attached to this corporate announcement in detailed form.
Yours faithfully,
Jyske Bank
Contact: Birger Krøgh Nielsen, CFO, tel. +45 89 89 64 44.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Idorsia Pharmaceuticals Ltd12.10.2026 07:00:00 CEST | Press release
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity
VALLOUREC12.10.2026 07:00:00 CEST | Press release
VALLOUREC AWARDED MAJOR CONTRACT BY TOTALENERGIES FOR THE ABSHERON GAS FIELD IN AZERBAIJAN
CGTN11.10.2026 14:03:56 CEST | Pressemeddelelse
CGTN: Sådan bruger Kina digital teknologi til at styrke kvinder globalt
F. Hoffmann-La Roche Ltd10.10.2026 23:40:00 CEST | Press release
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Chery Group10.10.2026 18:51:33 CEST | Press release
Evolving Luxury and Intelligence: LUXEED Set to Launch Global Media Drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
